{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:35Z","timestamp":1792787915724,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ19H280001"],"award-info":[{"award-number":["LQ19H280001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Projects of Medical and Health Technology Program in Zhejiang Province","award":["2019KY037"],"award-info":[{"award-number":["2019KY037"]}]},{"name":"Projects of Medical and Health Technology Program in Zhejiang Province","award":["2018KY312"],"award-info":[{"award-number":["2018KY312"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methadone is commonly considered an alternative opioid treatment for refractory cancer pain. This study aims to investigate the efficacy, safety, and cost of methadone in the treatment of refractory cancer pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted in patients who used methadone for refractory cancer pain from April 2016 to December 2020 at a cancer specialized hospital. Pain control, evaluated via pain score and breakthrough pain frequency, and adverse events of methadone were compared with analgesic regimens prior to methadone administration. The factors potentially affecting the switching outcome were analyzed via multivariate analysis. Moreover, the cost of pain control was estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety patients received methadone for poor pain control (74.4%), intolerable adverse events (10.0%), or both (15.6%) after prior opioid treatments. Sixty-four patients (71.1%) were successfully switched to methadone with median pain score significantly decreased from 4.0 to 2.0 (p\u2009&lt;\u20090.001) and median daily frequency of breakthrough pain from 3.0 to 0.0 (p\u2009&lt;\u20090.001) at a maintained median conversion ratio of 6.3 [interquartile range (IQR): 4.0\u201310.0] to prior opioid treatment. Similar adverse event profiles of constipation, nausea, vomiting, and dizziness were observed between methadone and prior opioid regimens. The median daily cost of analgesic regimens was significantly reduced from $19.5 (IQR: 12.3\u201346.2) to $10.8 (IQR: 7.1\u201318.7) (p\u2009&lt;\u20090.01) after switching to methadone. The 3-day switch method significantly improved the rate of successful switching compared with the stop and go method (odds ratio\u2009=\u20093.37, 95% CI: 1.30\u20138.76, p\u2009=\u20090.013).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Methadone is an effective, safe, and cost-saving treatment for patients with refractory cancer pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12904-022-01076-2","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T05:16:34Z","timestamp":1667366194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Methadone switching for refractory cancer pain"],"prefix":"10.1186","volume":"21","author":[{"given":"Haiying","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Like","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoneng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"21","key":"1076_CR1","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1200\/JCO.2002.02.121","volume":"20","author":"NF Esnaola","year":"2002","unstructured":"Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA, et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol. 2002;20(21):4361\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1076_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3322\/caac.21453","volume":"68","author":"BM Scarborough","year":"2018","unstructured":"Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin. 2018;68(3):182\u201396.","journal-title":"CA Cancer J Clin"},{"key":"1076_CR3","doi-asserted-by":"crossref","unstructured":"van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007, 18(9):1437\u20131449.","DOI":"10.1093\/annonc\/mdm056"},{"issue":"7","key":"1076_CR4","first-page":"Cd012592","volume":"7","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):Cd012592.","journal-title":"Cochrane Database Syst Rev"},{"key":"1076_CR5","doi-asserted-by":"crossref","unstructured":"Fernandes M, Schelotto M, Doldi PM, Milani G, Ariza Manzano AA, Perera Valdivia D, et al. IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain. F1000Res 2021, 10:42.","DOI":"10.12688\/f1000research.27809.1"},{"issue":"1","key":"1076_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/jpm.2011.0326","volume":"15","author":"DC Currow","year":"2012","unstructured":"Currow DC, Spruyt O, Hardy J. Defining refractory pain in cancer for clinicians and researchers. J Palliat Med. 2012;15(1):5\u20136.","journal-title":"J Palliat Med"},{"issue":"2","key":"1076_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jpainsymman.2015.02.029","volume":"50","author":"S McLean","year":"2015","unstructured":"McLean S, Twomey F. Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. J Pain Symptom Manage. 2015;50(2):248\u201359.e241.","journal-title":"J Pain Symptom Manage"},{"issue":"3\u20134","key":"1076_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/15360288.2019.1666956","volume":"33","author":"SY Khoo","year":"2019","unstructured":"Khoo SY, Aziz FA, Nambbiar P. Opioid Rotation to Methadone for Refractory Cancer Pain: A Case Series. J Pain Palliat Care Pharmacother. 2019;33(3\u20134):125\u201330.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"11","key":"1076_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1089\/jpm.2013.0222","volume":"16","author":"W Rhondali","year":"2013","unstructured":"Rhondali W, Tremellat F, Ledoux M, Ciais JF, Bruera E, Filbet M. Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. J Palliat Med. 2013;16(11):1382\u20137.","journal-title":"J Palliat Med"},{"issue":"2","key":"1076_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5055\/jom.2007.0048","volume":"3","author":"DJ Axelrod","year":"2007","unstructured":"Axelrod DJ, Reville B. Using methadone to treat opioid-induced hyperalgesia and refractory pain. J Opioid Manag. 2007;3(2):113\u20134.","journal-title":"J Opioid Manag"},{"issue":"7","key":"1076_CR11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P","volume":"72","author":"JC Crews","year":"1993","unstructured":"Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer. 1993;72(7):2266\u201372.","journal-title":"Cancer"},{"issue":"2\u20133","key":"1076_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0014-2999(99)00270-8","volume":"373","author":"JG Liu","year":"1999","unstructured":"Liu JG, Liao XP, Gong ZH, Qin BY. The difference between methadone and morphine in regulation of delta-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. Eur J Pharmacol. 1999;373(2\u20133):233\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1076_CR13","first-page":"1263","volume":"274","author":"EE Codd","year":"1995","unstructured":"Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263\u201370.","journal-title":"J Pharmacol Exp Ther"},{"key":"1076_CR14","doi-asserted-by":"crossref","unstructured":"Hanna V, Senderovich H. Methadone in Pain Management: A Systematic Review. J Pain 2020.","DOI":"10.1136\/rapm-2021-ESRA.80"},{"issue":"7","key":"1076_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1742-1241.2008.01990.x","volume":"63","author":"W Leppert","year":"2009","unstructured":"Leppert W. The role of methadone in cancer pain treatment\u2013a review. Int J Clin Pract. 2009;63(7):1095\u2013109.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"1076_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/15360288.2014.938883","volume":"28","author":"P Good","year":"2014","unstructured":"Good P, Afsharimani B, Movva R, Haywood A, Khan S, Hardy J. Therapeutic challenges in cancer pain management: a systematic review of methadone. J Pain Palliat Care Pharmacother. 2014;28(3):197\u2013205.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"5","key":"1076_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595\u2013612.","journal-title":"Pain Med"},{"issue":"3","key":"1076_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jpainsymman.2018.12.001","volume":"57","author":"ML McPherson","year":"2019","unstructured":"McPherson ML, Walker KA, Davis MP, Bruera E, Reddy A, Paice J, et al. Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. J Pain Symptom Manage. 2019;57(3):635\u201345 e634.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1076_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","volume":"15","author":"R Chou","year":"2014","unstructured":"Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15(4):321\u201337.","journal-title":"J Pain"},{"key":"1076_CR20","doi-asserted-by":"crossref","unstructured":"Tan C, Wong JF, Yee CM, Hum A. Methadone rotation for cancer pain: an observational study. BMJ Support Palliat Care 2020.","DOI":"10.1136\/bmjspcare-2019-002175"},{"key":"1076_CR21","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE) (Version 5.0)."},{"key":"1076_CR22","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Adult Cancer pain. 2020. Version 1."},{"issue":"10","key":"1076_CR23","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.1999.17.10.3307","volume":"17","author":"S Mercadante","year":"1999","unstructured":"Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17(10):3307\u201312.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1076_CR24","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1200\/JCO.2001.19.11.2898","volume":"19","author":"S Mercadante","year":"2001","unstructured":"Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19(11):2898\u2013904.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1076_CR25","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.ejca.2011.06.047","volume":"47","author":"K Moksnes","year":"2011","unstructured":"Moksnes K, Dale O, Rosland JH, Paulsen \u00d8, Klepstad P, Kaasa S. How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. Eur J Cancer. 2011;47(16):2463\u201370.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1076_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-012-1228-3","volume":"68","author":"K Moksnes","year":"2012","unstructured":"Moksnes K, Kaasa S, Paulsen \u00d8, Rosland JH, Spigset O, Dale O. Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. Eur J Clin Pharmacol. 2012;68(8):1147\u201356.","journal-title":"Eur J Clin Pharmacol"},{"key":"1076_CR27","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Adult Cancer pain. 2019. Version 1."},{"issue":"3","key":"1076_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1526-4637.2012.01334.x","volume":"13","author":"S Mercadante","year":"2012","unstructured":"Mercadante S. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med. 2012;13(3):399\u2013404.","journal-title":"Pain Med"},{"issue":"5","key":"1076_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpainsymman.2016.05.022","volume":"52","author":"P Poulain","year":"2016","unstructured":"Poulain P, Berleur MP, Lefki S, Lefebvre D, Chvetzoff G, Serra E, et al. Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain). J Pain Symptom Manage. 2016;52(5):626\u201336.e621.","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"1076_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1089\/jpm.2018.0490","volume":"22","author":"S Okayama","year":"2019","unstructured":"Okayama S, Matsuda Y, Yoshikawa Y. A Comparative Study of Opioid Switching to Methadone for Cancer Pain Control in Successful and Unsuccessful Cases. J Palliat Med. 2019;22(7):844\u20137.","journal-title":"J Palliat Med"},{"issue":"4","key":"1076_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11912-006-0034-4","volume":"8","author":"J Bryson","year":"2006","unstructured":"Bryson J, Tamber A, Seccareccia D, Zimmermann C. Methadone for treatment of cancer pain. Curr Oncol Rep. 2006;8(4):282\u20138.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1076_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5694\/j.1326-5377.2000.tb139323.x","volume":"173","author":"OT Ayonrinde","year":"2000","unstructured":"Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173(10):536\u201340.","journal-title":"Med J Aust"},{"issue":"5","key":"1076_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/NMD.0000000000000978","volume":"207","author":"J Westermeyer","year":"2019","unstructured":"Westermeyer J, Thuras P, Yoon G, Kolla BP, Batres YCT, Dimitropoulos E. Methadone-Related Delirium: Prevalence, Causes, and Outcomes. J Nerv Ment Dis. 2019;207(5):371\u20137.","journal-title":"J Nerv Ment Dis"},{"issue":"2","key":"1076_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/cncr.24754","volume":"116","author":"HA Parsons","year":"2010","unstructured":"Parsons HA, de la Cruz M, El Osta B, Li Z, Calderon B, Palmer JL, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer. 2010;116(2):520\u20138.","journal-title":"Cancer"},{"issue":"11","key":"1076_CR35","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1007\/s00520-021-06211-y","volume":"29","author":"G Mammana","year":"2021","unstructured":"Mammana G, Bertolino M, Bruera E, Orellana F, Vega F, Peirano G, et al. First-line methadone for cancer pain: titration time analysis. Support Care Cancer. 2021;29(11):6335\u201341.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1076_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","volume":"21","author":"P F\u00fcrst","year":"2018","unstructured":"F\u00fcrst P, Lundstr\u00f6m S, Klepstad P, Runesdotter S, Strang P. Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment. J Palliat Med. 2018;21(2):177\u201381.","journal-title":"J Palliat Med"},{"issue":"6","key":"1076_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-022-01076-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12904-022-01076-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-022-01076-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T22:06:41Z","timestamp":1686089201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-022-01076-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1186\/s12904-022-01076-2","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been approved by Ethics Committee of Zhejiang Cancer Hospital (No. IRB-2022-86) and exemption from informed consent was allowed. Our study was performed in accordance with the Declaration of Helsinki and following relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}